Literature DB >> 18946496

Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber.

S Myhre1, P Henning, M Friedman, S Ståhl, L Lindholm, M K Magnusson.   

Abstract

Vectors based on Adenovirus type 5 (Ad5) are among the most common vectors in cancer gene therapy trials to date. However, for increased efficiency and safety, Ad5 should be de-targeted from its native receptors and re-targeted to a tumor antigen. We have described earlier an Ad5 vector genetically re-targeted to the tumor antigen HER2/neu by a dimeric version of the Affibody molecule ZH inserted in the HI-loop of the fiber knob of a coxsackie and adenovirus receptor-binding ablated fiber. This virus showed almost wild-type growth characteristics and infected cells through HER2/neu. Here we generate vectors with double specificity by incorporating two different Affibody molecules, ZH (HER2/neu-binding) and ZT (Taq polymerase-binding), at different positions relative to one another in the HI-loop. Receptor-binding studies together with viral production and gene transfer assays showed that the recombinant fiber with ZT in the first position and ZH in the second position (ZTZH) bound to both its targets, whereas surprisingly, the fiber with ZHZT was devoid of binding to HER2/neu. Hence, it is possible to construct a recombinant adenovirus with dual specificity after evaluating the best position for each ligand in the fiber knob.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18946496     DOI: 10.1038/gt.2008.160

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

Review 1.  Chapter two--Adenovirus strategies for tissue-specific targeting.

Authors:  Matthew S Beatty; David T Curiel
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 2.  Synthetic virology: engineering viruses for gene delivery.

Authors:  Caitlin M Guenther; Brianna E Kuypers; Michael T Lam; Tawana M Robinson; Julia Zhao; Junghae Suh
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-09-04

3.  A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer.

Authors:  M K Magnusson; R Kraaij; R M Leadley; C M A De Ridder; W M van Weerden; K A J Van Schie; M Van der Kroeg; R C Hoeben; N J Maitland; L Lindholm
Journal:  Hum Gene Ther       Date:  2011-10-12       Impact factor: 5.695

4.  Novel viral vectors utilizing intron splice-switching to activate genome rescue, expression and replication in targeted cells.

Authors:  Liane Viru; Gregory Heller; Taavi Lehto; Kalle Pärn; Samir El Andaloussi; Ülo Langel; Andres Merits
Journal:  Virol J       Date:  2011-05-19       Impact factor: 4.099

5.  Tropism-modification strategies for targeted gene delivery using adenoviral vectors.

Authors:  Lynda Coughlan; Raul Alba; Alan L Parker; Angela C Bradshaw; Iain A McNeish; Stuart A Nicklin; Andrew H Baker
Journal:  Viruses       Date:  2010-10-13       Impact factor: 5.818

Review 6.  Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancer.

Authors:  Julia Reetz; Ottmar Herchenröder; Brigitte M Pützer
Journal:  Viruses       Date:  2014-04-02       Impact factor: 5.048

7.  Development of an adenovirus vector vaccine platform for targeting dendritic cells.

Authors:  Piyush K Sharma; Igor P Dmitriev; Elena A Kashentseva; Geert Raes; Lijin Li; Samuel W Kim; Zhi-Hong Lu; Jeffrey M Arbeit; Timothy P Fleming; Sergey A Kaliberov; S Peter Goedegebuure; David T Curiel; William E Gillanders
Journal:  Cancer Gene Ther       Date:  2017-12-15       Impact factor: 5.987

Review 8.  Designer Oncolytic Adenovirus: Coming of Age.

Authors:  Alexander T Baker; Carmen Aguirre-Hernández; Gunnel Halldén; Alan L Parker
Journal:  Cancers (Basel)       Date:  2018-06-14       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.